Robotic Total Hip Arthroplasty Anesthesia Management

Robotic Total Hip Arthroplasty Anesthesia Management: Retrospective Study

Robotic arthroplasty is increasing in acceptance on a global scale as a result of advancements in orthopedic surgery technology. The investigators aimed to share their anesthesia management experience as well as compare robotic unilateral total hip arthroplasty with conventional surgical technique in this retrospective study.

Study Overview

• Status: Not yet recruiting
• Conditions: Joint Diseases; Hip Osteoarthritis; Anesthesia
• Intervention / Treatment: Procedure: the robot assisted total hip arthroplasty; Procedure: the conventional total hip arthroplasty

Detailed Description

This study was conducted after obtaining ethics committee approval.

The inclusion criteria were as follows: American Society of Anesthesiologists (ASA) physical status I-III patients between 40-85 years, elective unilateral THAs which were performed by a single senior orthopedic surgeon and orthopedic team between January 2021 and January 2023 under CSEA. Exclusion criteria were urgent surgery, bilateral surgery, previous surgery, missing data, and lost to follow-up in the perioperative period.

The routine anesthetic protocol for the TKA was as follows: A single dose of 0.5% hyperbaric bupivacaine between 15-10 mg was administered intratechally. Following this the epidural catheter was inserted 4 cm into the epidural space through the epidural needle and secured. The level of the sensory block was assessed using pin-prick and cold sensation tests, and motor block using the Bromage scale. The patients were followed in the postanesthesia care unit (PACU) after the surgery. Patients with a modified Aldrete scoring system ≥9 were considered to be eligible for the transfer from PACU to the service.

Pain was evaluated using a Visual Analogue Scale (VAS) with regular intervals. Data were collected from hospital's electronic database records, patient files, and anesthesia charts.

• Study Type: Observational
• Enrollment (Anticipated): 150

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with American Society of Anesthesiologists (ASA) physical status I-III and elective unilateral THAs between the ages of 40 and 85 will be analyzed.

Description

Inclusion Criteria:

• American Society of Anesthesiologists (ASA) physical status I-III
• Between 40-85 years
• Elective unilateral THAs which were performed by a single senior orthopedic surgeon
• Between January 2021 and January 2023 under CSEA.

Exclusion Criteria:

• Urgent surgery
• Bilateral surgery
• Previous surgery
• Missing data and lost to follow-up in the perioperative period

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Group rTHA (robotic total hip arthroplasty); the robot assisted total hip arthroplasty	Procedure: the robot assisted total hip arthroplasty; the robot assisted total hip arthroplasty
Group cTHA (conventional total hip arthroplasty); the conventional total hip arthroplasty	Procedure: the conventional total hip arthroplasty; the conventional total hip arthroplasty

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time	The duration of surgical procedures	Only in surgery time, an average of 3 hours]

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complications	Perioperative complications rates	After the end of surgery, in the first 1-month follow-up
Hospital discharge time	Time from the beginning of the operation to the discharge of hospital	Time from discharge from PACU to discharge from hospital, an average of 96 hours

Collaborators and Investigators

• Sponsor: Saglik Bilimleri Universitesi Gulhane Tip Fakultesi

Study record dates

Study Major Dates

• Study Start (Anticipated): April 1, 2023
• Primary Completion (Anticipated): May 1, 2023
• Study Completion (Anticipated): May 15, 2023

Study Registration Dates

• First Submitted: March 20, 2023
• First Submitted That Met QC Criteria: March 20, 2023
• First Posted (Actual): April 3, 2023

Study Record Updates

• Last Update Posted (Actual): April 5, 2023
• Last Update Submitted That Met QC Criteria: March 31, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Joint Diseases; Osteoarthritis, Hip
• Other Study ID Numbers: 2023-65

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No